Article info
Letter
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
- Correspondence to Dr Darren Plant, Centre for Musculoskeletal Research, The University of Manchester Centre for Genetics and Genomics Versus Arthritis, Manchester, UK; Darren.Plant{at}manchester.ac.uk
Citation
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
Publication history
- Received January 30, 2023
- Accepted July 22, 2023
- First published September 12, 2023.
Online issue publication
January 11, 2024
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Copyright information
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.